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Abstract
Purpose—Test the hypothesis that puerperal mastitis may alter immunity related to the mucin
(MUC) family of glycoproteins and lower risk for ovarian cancer.
Methods—In two case-control studies conducted in New England between 1998–2008, we
examined the association between self-reported mastitis and ovarian cancer in 1,483 women with
epithelial ovarian cancer and 1,578 controls. IgG1 antibodies against (MUC1) CA15.3 and
(MUC16) CA125 were measured using electrochemiluminescence assays in a subset of controls
(n=200). Preoperative CA125 was recorded in 649 cases. The association between ovarian cancer
and mastitis was assessed using unconditional logistic regression to calculate adjusted odds ratios,
OR, and 95% confidence intervals (CI). Associations between mastitis and anti-CA15.3 and anti-
CA125 antibodies and preoperative CA125 levels were evaluated using adjusted linear regression
models.
Results—Prior mastitis was associated with a significantly lower risk for ovarian cancer: OR
(and 95% CI) of 0.67 (0.48, 0.94) adjusted for parity, breastfeeding, and other potential
confounders. The association was strongest with 2 or more episodes of mastitis; and risk declined
progressively with increasing number of children and episodes of mastitis. Among controls, prior
mastitis was associated with significantly higher anti-CA15.3 and anti-CA125 antibody levels and,
among cases, with significantly lower preoperative CA125 levels.
Conclusion—Puerperal that mastitis may produce long-lasting anti-mucin antibodies that may
lower the risk for ovarian cancer, plausibly through enhanced immune surveillance. Studying
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immune reactions related to MUC1 and MUC16 in the 10–20% of breastfeeding women who
develop mastitis may suggest ways to duplicate its effects through vaccines based on both
antigens.
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INTRODUCTION
An estimated 22,280 women in the U.S. were diagnosed with and 15,500 died of ovarian
cancer in 2012 [1]. Prevention will require a comprehensive understanding of risk factors for
this deadly disease and underlying mechanisms. Ages at menarche and menopause, births,
and lengths of breastfeeding and oral contraceptive use (OC) are important reproductive
events—often aggregated to estimate number of ovulatory cycles which are directly
correlated with ovarian cancer risk [2]. Less easily explained by ovulation, events like
hysterectomy (without oophorectomy) and tubal ligation lower ovarian cancer risk and
endometriosis and genital talc use increase it [3,4,5]. To explain these associations, we
hypothesized that they alter ovarian cancer risk through effects related to the mucin (MUC)
family of cell surface glycoproteins, especially MUC1, or CA15.3, which is over-expressed
in many cancers including ovarian. Acute events, like hysterectomy or tubal ligation, release
a tumor-like form of MUC1 and elicit anti-MUC1 antibodies which signal enhanced
immune surveillance, thereby reducing ovarian cancer risk [6]. Conversely chronic events,
such as repeated ovulations, lead to more continuous exposure to MUC1, dampen mucin-
specific immunity, and produce immune tolerance of an emerging MUC1+ cancer. Key
elements of this model were confirmed in prospective data from the Nurses’ Health Study
[7].
Two protective events we considered were puerperal mastitis and mumps parotitis.
Regarding mastitis, we presented limited case-control data showing mastitis may lower
ovarian cancer risk [6]. Regarding mumps, we reviewed epidemiologic evidence that mumps
reduced risk for ovarian cancer and showed that individuals going through a mumps
infection do, in fact, have elevated levels of anti-MUC1 antibodies as well as elevated levels
of CA125, or MUC16 [8]. In this report, we present new case-control data on the association
between mastitis and ovarian cancer and examine plasma anti-MUC1 and anti-MUC16
antibody levels as possible biomarkers of an immune surveillance mechanism for ovarian
cancer risk reduction.
METHODS
Study Design and Population
Data for this study arose from the last two enrollment periods of a case-control study of
ovarian cancer in New England (period 4 (1998–2002) and period 5 (2003–2008)) described
elsewhere [9]. Briefly, 2,877 women residing in eastern Massachusetts and New Hampshire
with a diagnosis of ovarian cancer were identified through hospital tumor boards and
statewide cancer registries. Of these 2,206 (77%) were eligible and 1,588 (72%) agreed to
participate (1,483 epithelial and 105 non-epithelial ovarian cancers). 4,366 controls were
identified through a combination of drivers’ license and town resident lists, 2,940 (67%)
were eligible, 1,362 (46%) declined to participate and 1,578 (54%) were enrolled. Controls
were frequency matched to cases on age and state of residence.
After written informed consent, demographic information, reproductive and medical history,
and habits were assessed by in-person interviews. Approximately 95% of cases and controls
Cramer et al. Page 2
Cancer Causes Control. Author manuscript; available in PMC 2014 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
provided a blood sample at the time of the interview. Pathology reports were reviewed for
histologic type, grade, and stage of the ovarian cancer. From hospitals with searchable
electronic records, CA125 levels prior to therapy were recorded [10]. In period 4,
occurrence of mastitis was captured in responses to the question: “Did you have any
problems with breastfeeding?” In period 5, subjects were specifically asked if they ever had
a breast infection, how many episodes, whether they were associated with breastfeeding, and
age at first episode. This study was approved by Brigham and Women’s Hospital and
Dartmouth Medical Center’s institutional review boards.
Anti-CA125 and Anti-CA15.3 Antibody Detection
A sample of period 5 controls was selected for antibody assays. Forty controls were age-
matched from each of the following categories: 1) nulliparous, 2) parous and never
breastfed, 3) parous, breastfed, no mastitis, 4) parous, breastfed, 1 mastitis, and 5) parous,
breastfed, >1 mastitis. Plasma antibodies to CA125 and CA15.3 were measured using the
Meso Scale Discovery (MSD) electro-chemiluminescence (ECL) multiplex platform, which
compares favorably with standard ELISA and immunobead assays [11]. Antigen-grade
CA15.3 and CA125 purified from breast and ovarian cancer cell lines (Meridian Life
Sciences Inc, Memphis, TN) were coated on multi-spot plates by MSD and inspected for
coating quality control. The plates were provided to the Fichorova Laboratory for assay
optimization by standardized operational procedures. The final assay design included the
following steps: blocking with 200 μl/well MSD Blocker A for 1h followed by wash; adding
25 μl/well of MSD Assay Diluent and 2h incubation with samples (25 μl/ml) at multiple
dilutions (10, 50, 250, 1250) followed by PBS/0.05% Tween-20 wash; detection of human
IgG1 bound to the specific protein spots with MSD sulfoTag-labeled antibodies (1μg/ml) for
2h; washing and adding read buffer followed by detection of ECL using MSD Imager 2400.
A plasma pool prepared from 5 ovarian cancer patients with high anti-MUC1 antibodies
levels ELISA-determined previously [8] was used as a positive control. Split aliquots of this
pool were tested at the same dilutions as the test samples on each assay plate and served to
assess ECL inter-assay variation. The raw reading inter-plate coefficients of variation (CV)
for all plasma dilutions were 17–19% for anti-CA15.3 and 9–11% for anti-CA125. Based on
the most consistent inter-plate (CV<19%) and intra-plate (CV<5%) reproducibility, and the
lowest frequency of non-zero readings, we chose the 10-fold dilution data to describe
general relationships with mucin immunity.
Statistical Analysis
Associations between epidemiologic factors and mastitis among cases and controls were
identified by Chi-square and Fisher’s exact tests. Odds ratios and 95 percent confidence
intervals (CI) were calculated using unconditional logistic regression with adjustment for
age (continuous), study period, and study center. In addition, we included the following
ovarian cancer and/or mastitis risk factors to assess the association between mastitis and
ovarian cancer risk independent of these variables: menopausal status (pre, post), OC use
(never, <1 year, 1–5 years, >5 years), endometriosis, bladder infection, colitis, parity (0, 1,
2, 3, >3), smoking (never, <9 pack years, ≥ 9 pack years) and duration of breastfeeding
(never, <4 months, 4–9 months, 10–16 months, >16 months). Because puerperal mastitis
occurs predominantly among breastfeeding women, analyses were repeated in women who
had breastfed. The overall association between mastitis and ovarian cancer was quantified in
all cases and then separately for serous borderline, serous invasive, mucinous, endometrioid,
clear cell and other or undifferentiated histologic types of ovarian cancer.
Anti-CA15.3 antibodies, anti-CA125 antibodies, and preoperative CA125 levels were log-
normalized. Means and confidence intervals (CI) were calculated on the log scale and
exponentiated back to their original units (relative luminescence units for the antibodies and
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units/ml for CA125). To examine the specific effect of mastitis on anti-CA15.3 antibodies,
anti-CA125 antibodies, and preoperative CA125 levels, we used linear regression models
and adjusted for age, parity, breastfeeding, and additional variables possibly affecting levels
of these biomarkers (see footnote to Table 4). In a sensitivity analysis we repeated the linear
regression models using antibody levels that had been corrected for possible batch effects
[12].
RESULTS
Mastitis and Ovarian Cancer Risk Association
The likelihood of mastitis by various potential confounding factors is shown in Table 1.
Self-reported history of mastitis was lower in period 4 of the study than in period 5. In
controls, history of mastitis was more likely for premenopausal women, women with BMI
<25, non-smokers, women with a later age at first livebirth, non-hysterectomized women,
OC users, and women who breastfed more children or for a longer period. The latter three
variables were also significantly related to the likelihood of mastitis in cases. Other variables
predicting mastitis in cases were history of endometriosis or colitis and blood types O and
A. After restricting these analyses to women who had breastfeed, variables that continued to
predict a greater likelihood of mastitis were study period 5, premenopausal status (controls),
number of infants breastfed and total months of breastfeeding (cases and controls), OC use
(cases), endometriosis (cases), and colitis (cases). Variables examined but not included in
Table 1 because they were not associated with mastitis were age, Jewish ethnicity,
menopausal hormone use, history of infertility, genital talc use, fibroids, personal history of
breast cancer, and a family history of ovarian or (premenopausal) breast cancer (data not
shown).
History of puerperal mastitis was associated with significantly decreased risk for ovarian
cancer adjusted OR (and 95% CI) of 0.67 (0.48, 0.94) (Table 2). No significant associations
with age at first mastitis or years since first mastitis were observed. The association was
more apparent in those who had experienced 2 or more episodes of mastitis with an adjusted
OR (and 95% CI) of 0.34 (0.16, 0.72). When the analyses were restricted to women who had
breastfed, the comparable ORs (and 95% CIs) were: 0.65(0.46, 0.93) and 0.34(0.16, 0.73).
Examining the association within strata based upon number of livebirths, the association was
least apparent for those with 1 pregnancy and most apparent for those with 2 pregnancies—
the category with the largest number of subjects. Within each of these birth strata, history of
2 or more episodes of mastitis was associated with the lowest risk including women who had
only 1 pregnancy but 2 episodes of mastitis. The final rows in Table 2 illustrate the additive
effect of number of births and episodes of mastitis relative to women with one child and no
mastitis. There is a progressive decline in risk for ovarian cancer with number of births and
episodes of mastitis. Women who had 3 or more births had an OR (and 95% CI) of 0.59
(0.46, 0.77) if they had no mastitis but 0.20 (0.07, 0.61) if they had 2 or more episodes of
mastitis. Similar associations were observed if the data were restricted to those who had
breastfed, the comparable ORs (and 95% CIs) were: 0.57 (0.40, 0.82) and 0.20 (0.06,0.63).
The association between mastitis and reduced risk for ovarian cancer applied least to
mucinous histologic types of ovarian cancer (Table 3).
Anti-Mucin Antibodies Association with Mastitis and Ovarian Cancer Risk Factors
Table 4 shows how history of mastitis (and Table 1 variables) affected mean levels of anti-
CA15.3 and anti-CA125 antibodies in controls and preoperative CA125 levels in cases.
Compared to nulliparous women, women who had more than one episode of mastitis had a
37% increase in anti-CA15.3 and a 54% increase in anti-CA125 antibody levels. Both anti-
CA15.3 and anti-CA125 antibody levels were about 50% lower for controls who had 9 or
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more pack years of smoking compared to non-smokers, 24 to 43% lower for those with a
history of endometriosis, and about 50% lower for those with history of colitis (borderline
significance). Women with a history of bladder infections had about 70% higher levels of
both anti-CA15.3 and anti-CA125 antibodies. Adjusting for these and other variables,
compared to women without a history of mastitis, anti-CA15.3 antibody levels were 23 to
32% higher for controls: with any history of mastitis (p=0.02), 2 or more episodes of
mastitis (p=0.01), and mastitis among women with more than one child (p=0.02). Anti-
CA125 antibody levels were significantly higher for women who had more than 1 pregnancy
and mastitis (p=0.04). Mastitis was associated with a 51% lower level of (preoperative)
CA125 in cases (p=0.03). There was no clear trend in antibody levels with time since last
episode of mastitis. Results were similar when antibody levels were adjusted for potential
batch effects.
DISCUSSION
Puerperal mastitis affects about 10% of breastfeeding women in US surveys [13] but more
than 20% in some populations [14]. In this study, we confirmed our prior observation that
puerperal mastitis is associated with significantly decreased risk for ovarian cancer. The OR
(and CL) for “any mastitis” from the earlier study which relied upon responses to an open-
ended question [6] was 0.35 (0.16, 0.77) where the referent category was parous women
who never breastfed. In study 5 the comparable OR for “any mastitis” was slightly higher,
0.48 (0.32,0.72). Subjects who remembered to mention mastitis were likely those who
experienced multiple or more severe episodes. Indeed in Study 5 it appears that the
association may be largely confined to women who had experienced 2 or more episodes of
mastitis. Importantly, controls with history of mastitis had significantly higher anti-CA15.3
antibody levels. This is compatible with our original hypothesis that mastitis, similar to other
acute events like mumps and tubal ligation, releases a tumor-like form of MUC1 and leads
to anti-MUC1 antibodies that may reduce the risk of ovarian cancer, a MUC1-expressing
tumor. We also observed higher anti-CA125 levels in controls with past mastitis and lower
preoperative CA125 levels in cases with past mastitis.
Obvious confounders for the association between puerperal mastitis and ovarian cancer are
parity and breastfeeding. Thus we examined the association in all women adjusted for parity
and breastfeeding and then restricted to parous women who breastfed, with comparable and
significant effects of mastitis in both analyses. The effect was best seen for the largest birth
category (women with two children), but within all birth strata women with ≥2 episodes of
mastitis had the greatest degree of protection. Other potential confounders include those
related to mastitis occurrence including menopausal status, smoking history, OC use, and (in
cases) colitis and endometriosis. Controlling for these factors did not negate the association
between mastitis and reduced risk for ovarian cancer. Since the association is inverse,
preferential recall by cases cannot account for the results. More controls than cases said they
had mastitis in response to the open-ended question in period 4 and the closed-ended
question in period 5. Chance must always be considered as an explanation for a novel
finding, but seems less likely since the association was seen in two separate studies. Since
not all controls approached agreed to participate, selection bias is possible if controls who
were parous and breastfed were over-represented. However, our participation rate is not
substantially lower than other case-control studies of ovarian cancer [15] and the frequency
of livebirth and breastfeeding we observed among controls are not higher than the rates
recently reported in another US based study [16].
Little has been written on the topic of mastitis and cancer risk. In the pre-antibiotic era,
puerperal mastitis was sometimes treated with X-ray therapy, which appeared to be
associated with subsequent increased risk for breast cancer [17]. There is also a cohort study
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of women hospitalized for mastitis (not treated by radiotherapy) in Sweden which reported a
statistically non-significant relative risk for breast cancer of 1.23[18]. Studies based upon
women hospitalized for mastitis are not particularly relevant because the rate is only about 1
per 1000 deliveries [19]. Clearly, more human or animal studies specifically designed to
examine the mastitis-ovarian cancer association are needed.
MUC1 is expressed in normal breast tissue at low levels compared with its expression in
other organs [20]. Mammary expression of MUC1 increases during pregnancy and lactation
[21], and MUC1 is an abundant component of breast milk. MUC1 is readily identified in the
serum of pregnant and lactating women. Croce et al. reported that circulating anti-MUC1
antibodies can also be found in lactating women, proving that a humoral immune response
to MUC1 occurs [21]. In Croce’s study, the highest levels of anti-MUC1 antibodies were in
lactating women who were multiparous, consistent with our findings of higher antibody
levels in multiparous compared to uniparous women. Other than a case report of a woman
with advanced breast cancer who developed puerperal mastitis and generated a high level of
anti-MUC1 antibodies [22], there are no human data on MUC1 and anti-MUC1 antibodies
during mastitis. In-vitro studies using bovine mammary cells found that MUC1 expression is
up-regulated with exposure to bacterial endotoxin or to E. coli, a common pathogen in
bovine mastitis [23]. Thus, it is reasonable to postulate that increased expression of MUC1
during mastitis releases MUC1 exposing it to the host immune system and generating anti-
MUC1 antibodies.
MUC16 (CA125) is also expressed in human mammary tissue [24]. Like CA15.3, serum
CA125 is elevated during pregnancy above the normal cutoff levels in about 35% of women,
especially during the first trimester. CA125 declines in the second trimester but may
increase again at delivery [25]. CA125 is expressed in decidua and found in amniotic fluid,
suggesting that the source of serum CA125 during pregnancy is primarily from the uterus
rather than the breasts, as it likely is for CA15.3 in pregnancy [26]. Although CA125 is
present in colostrum [24], we found no published data to indicate that serum CA125 is
elevated in lactating women or those with mastitis. Nevertheless, we observed that a history
of mastitis was associated with elevated anti-CA125 antibodies in controls.
After restricting the analysis to subjects who breastfed, variables that predicted greater
likelihood of mastitis in both cases and controls, (other than study period) included number
of infants breastfed and duration of breastfeeding. These two variables may simply reflect
greater opportunity to have developed mastitis, although veterinary literature suggests
greater parity may increase the likelihood of bovine mastitis [27]. Fewer postmenopausal
controls reported mastitis, which could reflect fading memory of the event or that fewer
older women had breastfed compatible with secular trends in breastfeeding rates [28].
Variables that predicted higher rates of mastitis in cases included history of colitis and
endometriosis. Although we could find no supporting literature for these associations and,
while they may be due to chance, the fact that these events also affected anti-CA15.3 and
anti-CA125 antibody levels suggest they may be biologically important in mucin immunity,
as may be urinary tract infections (UTI) which were significantly associated with elevated
antibodies to both CA125 and CA15.3 in this study. The potential significance of these
associations may not be fully apparent until we have pre-diagnostic levels of anti-CA15.3
and anti CA125 antibodies in cases. We were not able to study bacterial type involved in
mastitis or UTI but this is likely to be an important determinant of immune response.
Of course CA15.3 and CA125 are best known as tumor markers. Both are expressed in
breast and ovarian cancer and other epithelial malignancies [29,30]. There is evidence that
anti-CA15.3 antibodies also occur during malignancy, and these may be associated with
better survival [31]. It has also been observed, both in cancer cases and healthy controls, that
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anti-CA15.3 antibodies may bind with CA15.3 to form immune complexes which can
interfere with detection of the antigen [32]. The inverse association between CA15.3 antigen
and anti-CA15.3 antibody levels should be examined also for CA125. Our observation that
mastitis may increase anti-CA125 antibodies which remain in circulation years after the
acute event, as shown in controls, permit the speculation that mastitis-induced antibodies
contributed to the lower pre-operative CA125 levels observed in cases who reported
mastitis. A limitation of our study is that the association between history of mastitis and
anti-mucin antibody levels could not be examined in ovarian cancer cases due to lack of
preoperative blood samples available for antibody analysis; and, thus, we could only
examine mastitis association with existing data on pre-operative CA125 levels.
In conclusion, puerperal mastitis is a common reproductive event that may lower ovarian
cancer risk—an effect that may be mediated through immune reactions to mucins and
signaled by elevated anti-CA15.3 and anti-CA125 antibodies. These observations are
important because they lend support to our model explaining a broad range of risk factors
for ovarian cancer through MUC1 immunity and because they suggest MUC16 should now
be incorporated into this model. Puerperal mastitis affects between 10–20% of breastfeeding
women, making “real time” mechanistic studies of the effect of mastitis feasible. Such
studies may advance ovarian cancer biology and suggest innovative approaches to ovarian
cancer prevention, including vaccines involving MUC1 and MUC16. To facilitate future
epidemiologic studies of ovarian and other cancers that express MUC1 and MUC16,
puerperal mastitis should become a routine part of a comprehensive past medical history and
questionnaires designed to assess cancer risk.
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